1. Introduction {#sec1}
===============

Breast cancer is still the most common cancer based on the 2018 prediction of the European Cancer Information System, and the leading cause of cancer related death in female \[[@bib1]\]. To worsen the scenario, breast cancer is also a heterogenous disease. According to the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011, it can be identified into four subtypes based on the immunohistochemical evaluation of hormone receptors (HR) including estrogen receptor (ER) and progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) \[[@bib2]\]. These subtypes, namely Luminal A, Luminal B, HER2 enriched and triple negative breast cancer (TNBC), possess distinct risk factors, distinct clinicopathological characteristics and distinct responses to therapies, which warrant administration of individualized treatments \[[@bib2]\].

Postmastectomy radiotherapy (PMRT), eliminating potential residual tumor microfoci, has been shown to reduce locoregional recurrence (LRR) as well as improve overall survival (OS) in women with locally advanced breast cancer in multiple randomized trails and meta-analyses \[[@bib3]\]. The national comprehensive cancer network (NCCN) guidelines hold PMRT as a standard therapy for those breast cancer patients with more than 4 positive axillary nodes, and strongly recommend it for patients with 1--3 positive axillary nodes \[[@bib4]\]. However, the application of PMRT in patients with T1-2N1 breast cancer is still controversy. The recommendation of PMRT in T1-2N1 patients by NCCN guidelines \[[@bib4]\] and European Society for Medical Oncology Clinical Practice Guidelines \[[@bib5]\] was mostly based on the meta-analysis published in 2014 by Early Breast Cancer Trialists' Collaborative Group (EBCTCG) \[[@bib6]\]. The analysis of 1133 patients with 1--3 positive lymph nodes treated with axillary dissection showed significantly reduced LRR rate and breast cancer mortality. Yet, this work was often questioned by the neglect of tumor stage during analysis and the old-fashioned treatment modalities \[[@bib7]\]. Besides, other recent meta-analyses and clinical research of PMRT in this specific group of breast cancer patients observed no significant effect or modest increase in OS \[[@bib8], [@bib9], [@bib10], [@bib11]\].

As a heterogenous disease, T1-2N1 breast cancer harbors a broad range of risks for disease progression \[[@bib12]\] and calls for more tailored treatment, especially in the era of precision medicine guided by molecular subtypes \[[@bib3]\]. Thus, we performed this retrospective analysis of T1-2N1 breast cancer patients according to subtypes trying to identify those patients who would benefit from PMRT.

2. Materials and methods {#sec2}
========================

We performed this retrospective analysis based on the SEER 18 registry database, which collected data on patient demographics, clinical and pathological characteristics, survival, and treatment modalities of cancer patients in the United States. Patients fitting the following criteria were included: female patients, diagnosed with pathologically confirmed invasive breast cancer between 2010 and 2014, tumor no larger than 5 cm, one to three lymph nodes invasion, no distant metastasis, mastectomy performed, and one primary carcinoma only. Patients who received radiotherapy before surgery were excluded from our analysis. Data included age at diagnosis, year of diagnosis, race (white, black, other and unknown), marital status(married, not married, and unknown), laterality, histology, grade (four-grade system), tumor size, number of positive lymph nodes, number of lymph nodes examined, subtypes (HR+/HER2-as Luminal A; HR+/HER2+ as Luminal B; HR-/HER2+ as HER2 enriched; HR-/HER2-as TNBC), reconstruction, chemotherapy (yes or no/unknown) and radiotherapy were extracted by SEER∗Stat software version 8.3.6 based on the November 2018 data submission \[[@bib13]\]. Since information pertaining to scope of regional lymph node surgery were not accessible, we redefined this variable based on the number of lymph node examined in the surgery, namely 1 to 3 lymph nodes classified as sentinel lymph node biopsy (SLNB), 4 to 9 as unknown, and more than 10 as axillary lymph node dissection (ALND).

The independent ethical committee/institutional review board of Fudan University Shanghai Cancer Center Ethical Committee declared our study exempt from approval.

3. Statistical analysis {#sec3}
=======================

Clinicopathological characteristics were compared using the Pearson's χ2 test. Overall survival (OS) and breast cancer-specific survival (BCSS) were defined as the time interval from diagnosis to death due to any cause or breast cancer. Kaplan-Meier analysis was performed to compare the survival between subgroups. Multivariate Cox regression models were built to assess the independent association with OS as well as BCSS and to estimate hazard ratios (HR) and their 95% confidence intervals (CI). Given the difference between patients with and without radiotherapy, propensity score matching (PSM) was applied to balance measurable confounders. Logistic regression was conducted to assess patient factors associated with survival, and patients were matched based on their estimated propensity using 1:1 matching via nearest method without replacement with a caliper of 0.05. Statistical analysis was performed using SPSS 22.0 (Chicago, IL, USA) and the R programming language (version 3.5.3; <https://www.r-project.org/>) in RStudio (version 0.99.902; <https://www.rstudio.com/>). Two-sided *P* values \< 0.05 were considered statistically significant.

4. Results {#sec4}
==========

4.1. Patient characteristics by PMRT {#sec4.1}
------------------------------------

A total of 16,521 female patients with T1-2N1 breast cancer were enrolled in our study. 5775 (35.0%) patients who received radiotherapy were classified as PMRT group, and the other 10,746 (65.0%) patients as Non-PMRT group. The demographic and clinicopathological characteristics of both groups were presented in [Table 1](#tbl1){ref-type="table"}. 6754 (40.9%) patients were diagnosed with T1 tumor and 9767(59.1%) patients with T2 tumor. The distribution of patients with one to three positive lymph nodes were 9826 (59.5%), 4364 (26.4%), and 2331 (14.1%) respectively. The number of patients presented with Luminal A, Luminal B, HER2 enriched, and TNBC breast cancer were 11,789 (71.4%), 2176 (13.2%), 849 (5.1%) and 1707 (10.3%), respectively. 5325 patients (32.2%) chose breast reconstruction, and 11,363 patients (68.8%) received chemotherapy. ALND were performed in 9167 patients (55.5%). The median follow-up time of our study was 48 months.Table 1Patient characteristics by radiotherapy.Table 1CharacteristicsRadiotherapyYesNoneNo.%No.%*P*Age (years)\<0.001 ≤46199334.5243622.7 47-55153326.5264424.6 56-65128022.2260824.3 ≥6696916.8305828.5Year of diagnosis\<0.001 2010--2012332357.5661261.5 2013--2014245242.5413438.5Race0.006 White441276.4839578.1 Black73612.7119211.1 Others62710.9115910.8Marital status\<0.001 Single199834.6409138.1 Married353461.2610056.8 Unknown2434.25555.2Histology0.208 Ductal469581.3865480.5 Lobular5299.29739.1 Others5519.5111910.4Laterality0.378 Right287749.8527549.1 Left289850.2547150.9Grade\<0.001 Ⅰ5679.8158314.7 Ⅱ244642.4498946.4 Ⅲ-Ⅳ257544.6389236.2 Unknown1873.22822.6Tumor size (cm)\<0.001 ≤2195933.9479544.6 2 to 5381666.1595155.4No. of positive lymph nodes\<0.001 1279348.4703365.4 2175730.4260724.3 3122521.2110610.3Scope of regional lymph node surgery0.002 SLNB92916.1196318.3 Unknown159227.6287026.7 ALND325456.3591355Subtypes\<0.001 Luminal A391067.7787973.3 Luminal B85614.8132012.3 HER2 enriched3005.25495.1 TNBC70912.39989.3Reconstruction0.001 None381966.1737768.6 Yes195633.9336931.4Chemotherapy\<0.001 None77213.4438640.8 Yes500386.6636059.2

As shown in [Table 1](#tbl1){ref-type="table"}, patients in the PMRT group were significantly younger (*P* \< 0.001), more likely to be black (P = 0.006) and married (*P* \< 0.001). Also, compared with Non-PMRT group, tumors in the PMRT group were more aggressive, presenting with poorer differentiation, larger size, more lymph node invasion, and higher chance of being TNBC (all *P* \< 0.001). Accordingly, higher portion of patients received chemotherapy (*P* \< 0.001) in the PMRT group.

4.2. Survival by PRMT among different cohorts {#sec4.2}
---------------------------------------------

The overall survival was significantly better for patients in PMRT group than the Non- PMRT group (*P* \< 0.0001, [Fig. 1](#fig1){ref-type="fig"}). The 5-year OS rate in PMRT group and Non- PMRT group were 0.898 (95% CI:0.889--0.908) and 0.867 (95% CI:0.860--0.846), respectively. Stratified by subtype, patients with Luminal A, Luminal B, Her-2 enriched and TNBC tumors all obtained survival benefit from radiotherapy (*P* \< 0.0001, *P* = 0.0091, *P* = 0.0017, and *P* = 0.012, respectively, [Fig. 1](#fig1){ref-type="fig"}). Similarly, compared with Non- PMRT group, favorable prognosis was observed in PMRT patients with one to three positive lymph nodes, T1 and T2 tumors (*P* = 0.00038, *P* = 0.00013, *P* \< 0.0001, *P* = 0.0011, and *P* \< 0.0001, respectively, [Fig. 2](#fig2){ref-type="fig"}). Yet, no BCSS difference by PMRT was observed in all the cohorts, except for patients with tumor larger than 2 cm (*P* = 0.024) or with 3 positive lymph nodes (*P* = 0.015, [Supplementary Figs. 1 and 2](#appsec1){ref-type="sec"}).Fig. 1Overall survival of breast cancer patients in the whole cohort (A), Luminal A subtype (B), Luminal B subtype (C), HER2 enriched subtype (D) and TNBC subtype (E).Fig. 1Fig. 2Overall survival of breast cancer patients with one positive lymph node (A), two positive lymph nodes (B), three positive lymph nodes (C), T1 tumor (D) and T2 tumor (E).Fig. 2

4.3. Survival benefit of PMRT by subtype and other factors {#sec4.3}
----------------------------------------------------------

Next, we performed multivariate Cox regression analysis in different cohorts according to different factors. As shown in [Table 2](#tbl2){ref-type="table"}, PMRT, together with tumor size, number of lymph nodes invasion, subtype, chemotherapy and reconstruction, were significantly independent prognostic predictors in the whole cohort (HR: 0.800, 95%CI: 0.714--0.897, *P* \< 0.001). In order to identify those patients who would benefit from PMRT, we performed subgroup analysis according to subtype, tumor size, number of positive lymph nodes and other clinicopathological factors. PMRT significantly reduced the risk of dying in Luminal A patients (HR: 0.759, 95% CI: 0.651--0.884, *P* \< 0.001), Yet it brought no significant survival advantage in Luminal B, TNBC or HER2 enriched subtype (*P* = 0.914, *P* = 0.124, *P* = 0.103, respectively, [Fig. 3](#fig3){ref-type="fig"}). After adjusting for other clinicopathological factors, PMRT was significantly correlated with prolonged survival in patients with one positive lymph node and three positive lymph nodes (HR: 0.838, 95% CI: 0.713--0.985, *P* = 0.032; HR: 0.637, 95% CI: 0.492--0.824, *P* = 0.001, respectively), but not in patients with two positive lymph nodes (*P* = 0.162, [Fig. 3](#fig3){ref-type="fig"}). Also, PMRT brought survival benefit in patients with T1 and T2 tumors (HR: 0.789, 95% CI: 0.623--0.998, *P* = 0.048; HR: 0.807, 95% CI: 0.709--0.920, *P* = 0.001, respectively, [Fig. 3](#fig3){ref-type="fig"}). Besides, radiotherapy bore prognostic significance among those patients who were older than 56 years old, single, white, spare from reconstruction and chemotherapy, and were with ductal, GradeⅡtumor (all *P* \< 0.05, [Fig. 3](#fig3){ref-type="fig"}). As for BCSS, PMRT was ruled out as an independent prognostic factor in the whole population (HR: 0.901, 95% CI: 0.785--1.034, P = 0.137, [Table 2](#tbl2){ref-type="table"}), though it reduced cancer-specific death risk in patients who were older than 66 years old, did not receive chemotherapy or reconstruction, and presented with larger tumor and more lymph node invasion ([Supplementary Fig. 3](#appsec1){ref-type="sec"}).Table 2Multivariate Cox regression of overall survival in the whole cohort.Table 2OSBCSSCharacteristicsHR95% CI*P*HR95% CI*P*Age(years) ≤46ReferenceReference 47-550.9360.786--1.1140.4560.9570.793--1.1540.644 56-651.2071.025--1.4210.0240.9890.820--1.1930.908 ≥662.1381.834--2.492\<0.0011.3871.156--1.666\<0.001Race WhiteReferenceReference Black1.0690.932--1.2250.3411.1150.941--1.3200.208 Others0.6320.520--0.768\<0.0010.5900.458--0.759\<0.001Marital status SingleReferenceReference Married0.6270.565--0.695\<0.0010.7370.647--0.839\<0.001 Unknown0.7470.595--0.9380.0120.7970.594--1.0700.131Histology DuctalReferenceReference Lobular0.7870.650--0.9530.0140.7430.562--0.9830.038 Others0.7970.667--0.9520.0120.7910.626--1.0000.050Grade ⅠReferenceReference Ⅱ1.2581.045--1.5140.0151.8071.313--2.487\<0.001 Ⅲ-Ⅳ1.8691.540--2.268\<0.0013.6202.624--4.994\<0.001 Unknown1.3350.945--1.8870.1012.5851.616--4.135\<0.001Tumor size (cm) ≤2ReferenceReference 2 to 51.7661.581--1.972\<0.0012.0861.799--2.420\<0.001No. of positive lymph nodes 1ReferenceReference 21.1851.056--1.3300.0041.1380.982--1.3190.086 31.4661.275--1.687\<0.0011.4551.222--1.733\<0.001Scope of regional lymph node surgery SLNBReferenceReference Unknown0.8020.693--0.9270.0030.7750.640--0.9380.009 ALND0.7060.616--0.808\<0.0010.6960.583--0.830\<0.001Subtypes Luminal AReferenceReference Luminal B0.9260.780--1.0980.3770.7580.603--0.9520.017 HER2 enriched1.1400.909--1.4310.2561.1720.894--1.5360.249 TNBC2.9392.583--3.345\<0.0013.3102.837--3.861\<0.001Reconstruction NoneReferenceReference Yes0.5580.483--0.644\<0.0010.6700.570--0.787\<0.001Chemotherapy NoneReferenceReference Yes0.5440.485--0.610\<0.0010.6610.568--0.769\<0.001Radiation NoneReferenceReference Yes0.8000.714--0.897\<0.0010.9010.785--1.0340.137Fig. 3Hazard ratio and 95% confidence interval for overall survival stratified by clinicopathological characteristics according to radiotherapy.Fig. 3

Furthermore, we analyzed the role of PMRT with a certain tumor size or number of positive lymph node within the four subtypes of breast cancer. As illustrated in [Fig. 4](#fig4){ref-type="fig"}, In Luminal A patients, PMRT was prognostic in T1, T2, one and three positive lymph nodes subgroups (HR: 0.616, 95% CI: 0.442--0.860, *P* = 0.004; HR: 0.801, 95% CI: 0.674--0.952, *P* = 0.012; HR: 0.767, 95% CI: 0.617--0.954, *P* = 0.017; HR: 0.607, 95% CI: 0.434--0.849, *P* = 0.004), but not in the two positive lymph nodes subgroup (*P* \> 0.05). Quite differently, it was not associated with OS in all the subgroups of Luminal B, TNBC, and HER2 enriched patients. And PMRT only improved BCSS in Luminal A patients with 3 positive lymph nodes (HR: 0.586, 95% CI: 0.384--0.895, P = 0.013, [Supplementary Fig. 4](#appsec1){ref-type="sec"}).Fig. 4Hazard ratio and 95% confidence interval for overall survival stratified by tumor size and number of positive lymph nodes in different subtypes of breast cancer patients according to radiotherapy.Fig. 4

Based these results above, we further crossed tumor size with number of positive lymph nodes to classify patients into six subgroups in the whole cohort and Luminal A subtype. As demonstrated in [Fig. 4](#fig4){ref-type="fig"}, [Fig. 5](#fig5){ref-type="fig"} patients with T1 tumor concomitant with one positive lymph node, as well as patients with T2 tumor concomitant with three positive lymph node would benefit from PMRT (HR: 0.619, 95% CI: 0.431--0.889, *P* = 0.009; HR: 0.595, 95% CI: 0.444--0.799, *P* = 0.001, respectively). The findings were similar in the Luminal A subtype. In consistence with the findings of BCSS above, PMRT was associated with better survival in Luminal A patients with tumor larger than 2 cm concomitant with 3 positive lymph nodes (HR: 0.563, 95% CI: 0.386--0.821, P = 0.003, [Supplementary Fig. 5](#appsec1){ref-type="sec"}).Fig. 5Hazard ratio and 95% confidence interval for overall survival stratified by tumor size and number of positive lymph nodes in the whole cohort and Luminal A patients according to radiotherapy.Fig. 5

There were 3312 patients diagnosed with T1 tumor concomitant with one positive lymph node in Luminal A subtype, and 680 out of them received PMRT. Kaplan-Meier analysis showed significant overall survival difference between patients with and without PMRT (*P* \< 0.0001, [Fig. 6](#fig6){ref-type="fig"}A). Cox model also demonstrated that radiotherapy was an independently prognostic factor for this cohort (HR: 0.381, 95% CI: 0.214--0.676, *P* = 0.001, [Supplementary Table 1](#appsec1){ref-type="sec"}). Since clinicopathological characteristic were not balanced between RT group and Non-RT group, as shown in [Supplementary Table 2](#appsec1){ref-type="sec"}, we performed PSM to eliminate the influence of confounding factors. There were 1348 patients in the matched cohort. No significant difference was observed between the two groups in matched cohort ([Supplementary Table 2](#appsec1){ref-type="sec"}), and standardized differences in observable characteristics were \<5%. Survival benefit of RT group sustained in the matched group (*P* = 0.026, [Fig. 6](#fig6){ref-type="fig"}B). Besides, PMRT secured its prognostic role for this specific cohort of patients in multifactor regression analysis (HR: 0.416, 95%CI: 0.213--0.813, *P* = 0.01, [Supplementary Table 1](#appsec1){ref-type="sec"}). BCSS showed no significant difference between patients with and without PMRT before and after PSM (*P* = 0.069, *P* = 0.66, respectively, [Supplementary Fig. 6](#appsec1){ref-type="sec"}).Fig. 6Overall survival of Luminal A breast cancer patients with T1 tumor and one positive lymph node before (A) and after (B) propensity score matching.Fig. 6

5. Discussion {#sec5}
=============

This is so far the largest population-based study investigating the efficacy of PMRT in T1-2N1 breast cancer patients according to molecular subtypes. Our data showed that the survival benefit of PMRT varied among different subtypes and different number of positive lymph nodes. Our study provide evidence to administrate PMRT for those T1-2N1 patients according to their subtypes.

Presently, molecular subtype of breast cancer is not recommended to guide the indication of radiotherapy, however many literatures have followed on the prognosis depending on the subtypes of breast cancer receiving radiotherapy in different clinical settings \[[@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20]\]. Few studies focused on the different role of PMRT for T1-2N1 patients according to subtypes. Our study found that Luminal A subtype breast cancer could gain significant overall survival benefit from PMRT. The additional advantage for TNBC patients was marginal (HR: 0.839, 95%CI: 0.679--1.04, *P* = 0.103), while HER2 positive patients (including Luminal B and HER2 enriched subtype) received no merits of survival. This finding was in line with a review by He et al. \[[@bib3]\], who concluded that a significantly prolonged OS was observed in Luminal A and TNBC patients treated with breast conserving surgery and conventional whole-breast irradiation. Chen et al. \[[@bib21]\] conducted a retrospective analysis of TNBC patients from one single institution and found PMRT was associated with lengthened disease-free survival (DFS) in patients with T1-2N1 disease. A study of 1369 patients published in 2015 discussed the role of PMRT in T1-2N1 breast cancer patients according to subtype \[[@bib18]\]. In this research, PMRT reduced LRR rate in HER2 enriched subtype and TNBC, but showed no effect on OS irrespective of subtypes. This work, though shed some light on the research of PMRT within the scope of molecular subtype, was blighted by small cohort and uncommon distribution of the four subtypes (33.0%, 42.9%, 11.9% and 12.2% for Luminal A, Luminal B, HER2 enriched and TNBC subtype respectively). The intrinsic mechanisms of radiosensitivity in Luminal A breast cancer were documented to be related with the ER signal pathway \[[@bib22]\], epidermal growth factor receptor and its downstream signals \[[@bib3],[@bib23]\]. The reasons for the radioresistance of HER2 positive breast tumors were associated with a loop-like HER2-NF-κB-HER2 pathway\[[@bib24]\] and epithelial-to-mesenchymal transition \[[@bib25]\]. In our analysis, we also found that PMRT increased OS in Luminal A subtype patients with T1 tumor concomitant with one positive lymph node. This may partly be explained by the fact that only half of the patients (1689/3312) in this subgroup received chemotherapy. Thus, the omission of PMRT for Luminal A patients warrants further exploration and verification. Given the lack of treatment modality for TNBC patients, PMRT, though with limited survival gain, still stands as an indispensable option.

11,363 patients (68.8%) in our study received chemotherapy, and we noticed that PMRT provided neither overall survival benefits (HR: 0.885, 95%CI: 0.772--1.02, P = 0.083) nor cancer-specific survival benefits for these patients (HR: 0.988, 95%CI: 0.846--1.155, P = 0.883). Our finding was consistent with other literatures. A multicenter analysis of 714 patients who were treated with modified radical mastectomy and adjuvant taxane-based chemotherapy in 12 hospitals between January 2006 and December 2010 found that PMRT had no significant impact on DFS, or OS in pT1-2N1 patients after a median follow-up duration of 69 months \[[@bib26]\]. A research published by Zeidan et al. \[[@bib27]\] in 2018 analyzed patients with T1-2N1 disease enrolled on the Breast International Group (BIG) 02--98 trial. 684 patients who received adjuvant anthracycline with or without taxane chemotherapy were included in this study, of whom 337 (49%) had additional PMRT. No benefit difference was noted in breast cancer-specific survival (84.3% vs 83.9%) nor OS (81.7% vs 78.3%) according to receipt of PMRT, though patients randomized to receive chemotherapy with no taxane showed lower LRR after PMRT (10-year LRR: 3.4% vs 9.1%; P = 0.02). Likewise, Abdel-Rahman\[[@bib28]\] found that PMRT brought no OS advantage in T1-2 N1 breast cancer patients enrolled in 3 prospective phase Ⅲ chemotherapy trials including the BIG 02--98, the Breast Cancer International Research Group (BCIRG) 001 and the BCIRG 005 trials. Herein, in the era of anthracycline and taxane-based adjuvant chemotherapy, for patients with pT1-2N1 disease who did receive chemotherapy, PMRT may be dispensable, though prospective studies are needed.

There are certain limitations to this study. First, the follow-up time is relatively short due to the fact that HER2 status in SEER database only becomes available since 2010. Thus, in order to balance between study cohort and follow-up time, we confine our study patients to those diagnosed from 2010 to 2014. Even so, PSM was only done in Luminal A subgroup patients. Second, we cannot obtain data on recurrent and/or metastasis rates or pattern, the analysis of LRR was not performed in our study. We believe that OS is a qualified endpoint as it takes PMRT-induced toxicities of mortality \[[@bib29]\] into consideration. Besides, other factors with certain guidance indication, such as the presence of lympho-vascular invasion, extranodal tumor extension, surgical margin status, the extent of irradiation and molecular medicine administration \[[@bib7]\] were not available from SEER database. Also, the chemotherapy regimen and administration of hormonal therapy were beyond our accessibility. The discrepancy between OS and BCSS may be attributable to this lack of information. Third, our study, as a retrospective research, might suffer from selection bias. The result of a prospective randomized controlled trial SUPREMO will be reported in 2023 \[[@bib30],[@bib31]\]. This trial randomized female breast cancer patients with T1-2N1, T3N0 or T2N0 disease to receive or not PMRT after mastectomy.

In conclusion, the current analysis demonstrates a beneficial impact for PMRT on overall survival among Luminal A subtype, not HER2 positive subtype, breast cancer patients with T1-2N1 disease. In this heterogenous arbitrarily defined subgroup, the option of PRMT should be stratified upon risks factors.
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